|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||75.96 - 76.99|
|52 Week Range||70.42 - 86.92|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||23.87|
|Earnings Date||Oct 26, 2021|
|Forward Dividend & Yield||3.00 (3.54%)|
|Ex-Dividend Date||Mar 04, 2021|
|1y Target Est||N/A|
These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term.
Jonathan Moore, one of the first employees of Vertex Pharmaceuticals Inc. and a key scientist behind the company's renowned cystic fibrosis drugs, has a new venture called Rectify Pharmaceuticals.
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.